MIMEDX to Host Second Quarter 2021 Operating and Financial Results Conference Call on August 4
Marietta, Ga., July 20, 2021 - MiMedx Group, Inc. (Nasdaq: MDXG) will report its financial results for Q2 2021 on August 3, 2021, after market close. The company specializes in regenerative medicine using amniotic tissue and has a pipeline aimed at musculoskeletal conditions. A conference call will be held on August 4, 2021, at 8:30 am ET to discuss the results. MiMedx boasts a portfolio of over two million allografts supplied, highlighting its stronghold in the healthcare sector.
- Strong position in regenerative medicine with patented processes.
- Over two million allografts supplied, indicating market reach and acceptance.
- None.
MARIETTA, Ga., July 20, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it will report operating and financial results for the second quarter ended June 30, 2021 after the market close on Tuesday, August 3, 2021. MIMEDX management will host a webcast and conference call to review its results on Wednesday, August 4, 2021, beginning at 8:30 am Eastern Time.
The conference call can be accessed using the following information:
Webcast: https://edge.media-server.com/mmc/p/2gfy7rx3
U.S. Investors: 877-359-9508
International Investors: 224-357-2393
Conference ID: 8777681
A replay of the webcast will be available for approximately 30 days on the Company’s website at www.mimedx.com following the conclusion of the event.
About MIMEDX
MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a base business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.
Contact:
Investors
Jack Howarth
404-360-5681
jhowarth@mimedx.com
FAQ
When will MiMedx release its Q2 2021 financial results?
What is the conference call date for MiMedx's Q2 2021 results?
What products does MiMedx focus on?
How many allografts has MiMedx supplied?
